期刊文献+
共找到1,218篇文章
< 1 2 61 >
每页显示 20 50 100
Virtual Screening and Structure Generation Applied to Drug Design
1
作者 FAN B.T. A. PANAYE J-P. DOUCET 《合成化学》 CAS CSCD 2004年第z1期14-14,共1页
关键词 drug design STRUCTURE generATION 3D-QSAR DOCKING Virtual SCREENING
下载PDF
Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review
2
作者 Md. Imtiaz Hasan Shahnaz Akter Shimu +3 位作者 Akhi Akther Ishrat Jahan Md. Hamiduzzaman A. H. M. Nazmul Hasan 《Journal of Biosciences and Medicines》 2021年第10期23-39,共17页
Development of generic drug product by pharmaceutical industry is a scientific and technical approach which is totally different from developing a reference or innovator product. Most of the developing countries focus... Development of generic drug product by pharmaceutical industry is a scientific and technical approach which is totally different from developing a reference or innovator product. Most of the developing countries focus on developing the generic drug products because huge amount of investment is required for innovation and to develop reference product. The generic medicine has to be bioequivalent to the innovator drug and ensure the same biological effect with proper safety and efficacy. Nowadays, the pharmaceutical industries focus on the development of generic product as this does not require that much time and cost compared to the innovator company. But development of generic product is also difficult as it contains the same therapeutic efficacy as innovator. The development approach is based on the target market, i.e. US market, EU market. If a manufacturer targets the US market, then all excipients should be USP grade, analysis should be conducted by USP method or in-house method and stability studies as well. Prior and during the development of generic drug product API selection, dosage form selection, reference product selection and characterization, formulation development, analytical method development, tech transfer or submission batch are prime concern. Then again, bioequivalence study, drug registration procedure and commercialization of the generic product considering regulatory guidance of respective regulatory agencies and the approaches taken by the regulatory agencies for the development of registration of generic medicines are also crucial as well for the development of generic drug product. The aim of this study was to review the entire stage of a generic drug development by a generic pharmaceutical company. 展开更多
关键词 generic drug Reference Product Pre-Formulation NDA
下载PDF
Next generation sequencing for profiling expression of miRNAs: technical progress and applications in drug development
3
作者 Jie Liu Steven F. Jennings +1 位作者 Weida Tong Huixiao Hong 《Journal of Biomedical Science and Engineering》 2011年第10期666-676,共11页
miRNAs are non-coding RNAs that play a regulatory role in expression of genes and are associated with diseases. Quantitatively measuring expression levels of miRNAs can help understanding the mechanisms of human disea... miRNAs are non-coding RNAs that play a regulatory role in expression of genes and are associated with diseases. Quantitatively measuring expression levels of miRNAs can help understanding the mechanisms of human diseases and discovering new drug targets. There are three major methods that have been used to measure the expression levels of miRNAs: real-time reverse transcription PCR (qRT-PCR), microarray, and the newly introduced next-generation sequencing (NGS). NGS is not only suitable for profiling of known miRNAs that qRT-PCR and microarray can do too but also able to detect unknown miRNAs that the other two methods are incapable. Profiling of miRNAs by NGS has been progressed rapidly and is a promising field for applications in drug development. This paper will review the technical advancement of NGS for profiling miRNAs, including comparative analyses between different platforms and software packages for analyzing NGS data. Examples and future perspectives of applications of NGS profiling miRNAs in drug development will be discussed. 展开更多
关键词 MIRNAS Next-generation SEQUENCING EXPRESSION Data Analysis drug Development
下载PDF
Knowledge about the Management of Anti-Epileptic Drug Treatment among General Practitioners in Brazzaville, Congo
4
作者 Josué Euberma Diatewa Inès Frédérique Nsondé-Mondzié +4 位作者 Dinah Happhia Boubayi Motoula-Latou Eliot Prince Galiéni Sounga-Banzouzi Yacouba Kaba Ghislain Armel Mpandzou Paul Macaire Ossou-Nguiet 《Neuroscience & Medicine》 2023年第2期9-28,共20页
Background: Epilepsy is a chronic brain disorder. It often leads to disabilities and handicaps. In Africa, epilepsy is almost exclusively treated by general practitioners (GPs) because of a shortage of epilepsy specia... Background: Epilepsy is a chronic brain disorder. It often leads to disabilities and handicaps. In Africa, epilepsy is almost exclusively treated by general practitioners (GPs) because of a shortage of epilepsy specialists. It is therefore important to know the level of knowledge about epilepsy among GPs in order to improve their skills. Objectives: To assess the level of knowledge about the management of anti-epileptic drug treatment among GPs in Brazzaville;to investigate the relationship between demographic factors and GPs’ knowledge. Methods: This was a cross-sectional analytical study. It was conducted from 20 July to 1 September 2021. It focused on GPs working in public hospitals and private care centers in Brazzaville. Information on treatment aspects was collected through a standardized 11-item questionnaire. Results: Among the 137 participants, there were 84 (61.3%) men and 53 (38.7%) women. Of these participants, 36 (26.3%) were trained in Congo versus 101 (73.7%) in other countries. Only 21 (15.3%) GPs had good knowledge about the management of anti-epileptic drug treatment. The overall average knowledge score among GPs was low (31.4%). No significant associations were found between low and good levels of knowledge and gender (OR = 1.03;95% CI = 0.40 - 2.68;p = 1.000), age groups (OR 0.05), training country (OR = 0.62;95% CI = 0.19 - 1.98;p = 0.591), practice hospital (OR = 0.40;95% CI = 0.05 - 3.20;p = 0.695) and duration of professional experience (OR 0.05). Conclusion: The study population has insufficient knowledge about the management of anti-epileptic drug treatment. Demographic factors have no impact on GPs’ knowledge. Epilepsy education programs are needed to improve GPs’ knowledge and skills. 展开更多
关键词 EPILEPSY drug Treatment general Practitioners KNOWLEDGE BRAZZAVILLE
下载PDF
Increased frequency of angina attacks caused by switching a brand-name vasodilator to a generic vasodilator in patients with vasospastic angina:Two case reports 被引量:1
5
作者 Remi Goto-Semba Yuichi Fujii +2 位作者 Tomohiro Ueda Chikage Oshita Hiroki Teragawa 《World Journal of Cardiology》 CAS 2018年第3期15-20,共6页
It is well known that calcium channel blockers(CCBs) are the first line of therapy for vasospastic angina(VSA). Here, we report two cases of VSA with an increase in the frequency of angina attacks after switching from... It is well known that calcium channel blockers(CCBs) are the first line of therapy for vasospastic angina(VSA). Here, we report two cases of VSA with an increase in the frequency of angina attacks after switching from a brand-name to a generic CCB. In both cases, angina recurred upon switching from a brand-name CCB to a generic CCB during follow-up. The patients' condition improved upon switching back to the original CCB. Both cases involved a high severity of VSA, based on the results of spasm provocation testing. These findings suggest that, in some patients with severe VSA, the frequency of angina attacks increases when switching from a brand-name CCB to a generic CCB. Cardiologists should consider this factor when prescribing drugs for angina. 展开更多
关键词 Vasospastic ANGINA ACETYLCHOLINE Brandname drugS generIC drugS Refractory CHEST pain
下载PDF
pLoc-mGpos: Incorporate Key Gene Ontology Information into General PseAAC for Predicting Subcellular Localization of Gram-Positive Bacterial Proteins 被引量:4
6
作者 Xuan Xiao Xiang Cheng +2 位作者 Shengchao Su Qi Mao Kuo-Chen Chou 《Natural Science》 2017年第9期330-349,共20页
The basic unit in life is cell.?It contains many protein molecules located at its different organelles. The growth and reproduction of a cell as well as most of its other biological functions are performed via these p... The basic unit in life is cell.?It contains many protein molecules located at its different organelles. The growth and reproduction of a cell as well as most of its other biological functions are performed via these proteins. But proteins in different organelles or subcellular locations have different functions. Facing?the avalanche of protein sequences generated in the postgenomic age, we are challenged to develop high throughput tools for identifying the subcellular localization of proteins based on their sequence information alone. Although considerable efforts have been made in this regard, the problem is far apart from being solved yet. Most existing methods can be used to deal with single-location proteins only. Actually, proteins with multi-locations may have some special biological functions that are particularly important for drug targets. Using the ML-GKR (Multi-Label Gaussian Kernel Regression) method,?we developed a new predictor called “pLoc-mGpos” by in-depth extracting the key information from GO (Gene Ontology) into the Chou’s general PseAAC (Pseudo Amino Acid Composition)?for predicting the subcellular localization of Gram-positive bacterial proteins with both single and multiple location sites. Rigorous cross-validation on a same stringent benchmark dataset indicated that the proposed pLoc-mGpos predictor is remarkably superior to “iLoc-Gpos”, the state-of-the-art predictor for the same purpose.?To maximize the convenience of most experimental scientists, a user-friendly web-server for the new powerful predictor has been established at http://www.jci-bioinfo.cn/pLoc-mGpos/, by which users can easily get their desired results without the need to go through the complicated mathematics involved. 展开更多
关键词 Multi-Target drugs Gene ONTOLOGY Chou’s generAL PseAAC ML-GKR Chou’s Metrics
下载PDF
Commentary: Unexpected Novel Chemical Weapon Agents Designed by Innocuous Drug-Development AI (Artificial Intelligence) Algorithm
7
作者 Robert B. Raffa Joseph V. Pergolizzi Jr. +1 位作者 Thomas Miller Daniel Motto 《Pharmacology & Pharmacy》 CAS 2022年第7期225-229,共5页
Recent publications reveal the disturbing information that a minor edit to an algorithm being used for designing legitimate drug candidates redirected the program in a way that resulted in the surprising design of nov... Recent publications reveal the disturbing information that a minor edit to an algorithm being used for designing legitimate drug candidates redirected the program in a way that resulted in the surprising design of novel chemical warfare agent candidates. Although this outcome was not the result of nefarious intent, and appropriate chemical defense authorities were notified, the potential implications of some misapplication of a drug-design algorithm for nefarious purposes are clear. This Commentary summarizes how otherwise benign Artificial Intelligence (AI) algorithms used for drug discovery can be easily reversed to design novel chemical warfare agents for which no effective antidote will be available, or perhaps even envisioned. 展开更多
关键词 Artificial Intelligence drug Discovery Chemical Weapons Machine Learning generative Model Toxicity Prediction
下载PDF
Psychotic due to bath salts and methamphetamines:emergency cesarean section under general anesthesia 被引量:1
8
作者 Nina Schloemerkemper 《The Journal of Biomedical Research》 CAS CSCD 2018年第4期311-313,共3页
The use of "bath salts" or other new psychoactive substances,otherwise known as "legal highs",is increasing.Illicit drug use during pregnancy is not uncommon.Nevertheless,literature reporting bath salts and their ... The use of "bath salts" or other new psychoactive substances,otherwise known as "legal highs",is increasing.Illicit drug use during pregnancy is not uncommon.Nevertheless,literature reporting bath salts and their effect on pregnancy is scant.Besides,there seems to be no literature about bath salts and conduct of general anesthesia.This case report describes a general anesthetic for the surgical delivery of an infant to a woman under the acute influence of bath salts and methamphetamines. 展开更多
关键词 bath salts psychoactive substance legal high designer drug methamphetamine general anesthesia cesarean section
下载PDF
Exploring unbinding mechanism of drugs from SERT via molecular dynamics simulation and its implication in antidepressants
9
作者 谭新官 刘雪峰 +2 位作者 庞铭慧 王雨晴 赵蕴杰 《Chinese Physics B》 SCIE EI CAS CSCD 2023年第8期510-519,共10页
The human serotonin transporter(SERT)terminates neurotransmission by removing serotonin from the synaptic cleft,which is an essential process that plays an important role in depression.In addition to natural substrate... The human serotonin transporter(SERT)terminates neurotransmission by removing serotonin from the synaptic cleft,which is an essential process that plays an important role in depression.In addition to natural substrate serotonin,SERT is also the target of the abused drug cocaine and,clinically used antidepressants,escitalopram,and paroxetine.To date,few studies have attempted to investigate the unbinding mechanism underlying the orthosteric and allosteric modulation of SERT.In this article,the conserved property of the orthosteric and allosteric sites(S1 and S2)of SERT was revealed by combining the high resolutions of x-ray crystal structures and molecular dynamics(MD)simulations.The residues Tyr95 and Ser438 located within the S1 site,and Arg104 located within the S2 site in SERT illustrate conserved interactions(hydrogen bonds and hydrophobic interactions),as responses to selective serotonin reuptake inhibitors.Van der Waals interactions were keys to designing effective drugs inhibiting SERT and further,electrostatic interactions highlighted escitalopram as a potent antidepressant.We found that cocaine,escitalopram,and paroxetine,whether the S1 site or the S2 site,were more competitive.According to this potential of mean force(PMF)simulations,the new insights reveal the principles of competitive inhibitors that lengths of trails from central SERT to an opening were~18A for serotonin and~22 A for the above-mentioned three drugs.Furthermore,the distance between the natural substrate serotonin and cocaine(or escitalopram)at the allosteric site was~3A.Thus,it can be inferred that the potent antidepressants tended to bind at deeper positions of the S1 or the S2 site of SERT in comparison to the substrate.Continuing exploring the processes of unbinding four ligands against the two target pockets of SERT,this study observed a broad pathway in which serotonin,cocaine,escitalopram(at the S1 site),and paroxetine all were pulled out to an opening between MT1b and MT6a,which may be helpful to understand the dissociation mechanism of antidepressants. 展开更多
关键词 human serotonin transporter(SERT) comprehensive molecular dynamics(MD)simulation drug design molecular mechanics/generalized Born surface area(MM/GBSA)method
下载PDF
两种地诺孕素治疗子宫内膜异位症的临床疗效及不良反应对比 被引量:1
10
作者 刘倩 张家宁 +3 位作者 张双 刘青蓝 张保寅 孙楠 《中国临床药理学与治疗学》 CAS CSCD 北大核心 2024年第5期527-534,共8页
目的:评价地诺孕素仿制药和原研药在治疗子宫内膜异位症中的临床疗效和安全性,为地诺孕素临床用药提供依据。方法:收集我院2022年8月至2023年8月地诺孕素治疗子宫内膜异位症的患者资料,分为两组,分别给予地诺孕素仿制药或原研药地诺孕素... 目的:评价地诺孕素仿制药和原研药在治疗子宫内膜异位症中的临床疗效和安全性,为地诺孕素临床用药提供依据。方法:收集我院2022年8月至2023年8月地诺孕素治疗子宫内膜异位症的患者资料,分为两组,分别给予地诺孕素仿制药或原研药地诺孕素2 mg/d,口服,连续治疗6个月。分别在3个月和6个月对两组患者进行随访调查,比较仿制药和原研药治疗子宫内膜异位症相关疼痛的临床疗效和不良反应发生情况。结果:仿制药组和原研药组患者的盆腔相关疼痛均明显降低(P<0.05),仿制药组下降了(34.0±3.0)mm,原研药组下降了(34.5±3.9)mm。最常见的异常出血情况,仿制药组、原研药组患者的发生率分别为93%和90%,无统计学差异。结论:地诺孕素国产仿制药和原研药在临床疗效相似,安全性一致。 展开更多
关键词 地诺孕素 仿制药 原研药 子宫内膜异位症
下载PDF
Designing General Anesthetics That Have a Better Safety Profile
11
作者 Robert B. Raffa Joseph V. Pergolizzi Jr. Robert Taylor Jr. 《Pharmacology & Pharmacy》 2019年第10期407-415,共9页
General anesthetics constitute some of the most important and widely-used therapeutic drugs in the pharmacotherapeutic armamentarium. They are routinely used effectively and with adequate precaution-safety throughout ... General anesthetics constitute some of the most important and widely-used therapeutic drugs in the pharmacotherapeutic armamentarium. They are routinely used effectively and with adequate precaution-safety throughout the world for a multitude of clinical applications, predominantly as adjunctive agents for surgical procedures. Nevertheless, they have potential adverse effects (such as a drop in blood pressure and the inhibition of steroid production), particularly in vulnerable populations such as the very young and the frail elderly. It would be desirable therefore to have alternative agents that are just as efficacious, but have a better safety profile in a broader spectrum of patients. Toward this end, an anesthetic based on a unique chemical core (viz., an N-arylpyrrole derivative) has been reported in preclinical models to produce anesthetic effects without hemodynamic suppression. This lead could pave the way for new general anesthetics that are safer and easier to use. 展开更多
关键词 general ANESTHETIC INTRAVENOUS drug Discovery GABAA Receptor Molecular Modeling
下载PDF
Clinical Experience with Generic Rasagiline (Ralago<sup>&reg;</sup>) in Patients with Parkinson’s Disease: An Open-Label, Multicenter, Observational Study
12
作者 Dávid Pintér Júlia Lajtos +1 位作者 József Janszky Norbert Kovács 《Advances in Parkinson's Disease》 2019年第2期18-34,共17页
Background: Antiparkinsonian pharmacotherapy represents one of the most important expenses related to Parkinson’s disease. The application of generic drugs may help to reduce the economic burden of the disease;howeve... Background: Antiparkinsonian pharmacotherapy represents one of the most important expenses related to Parkinson’s disease. The application of generic drugs may help to reduce the economic burden of the disease;however, efficacy and safety of these products have been less studied. Objective: To investigate the efficacy and safety of generic rasagiline (Ralago?) from a clinical perspective. Methods: The Clinical Global Impression of Severity scale was used to rate the most important motor and non-motor symptoms at baseline and 12 weeks after the initiation of Ralago?. Patients also identified symptoms which were the main sources of their disability and distress in everyday life. Results: A total of 499 patients were enrolled (231 females, mean age: 73.2 ± 9.1 years, mean duration of disease: 3.6 ± 3.7 years). Of them, 486 patients completed the study protocol. Both motor and non-motor symptoms showed improvement during 12-week Ralago? treatment. Adverse events were rare, and the majority of them were not considered as serious. Conclusions: The generic rasagiline (Ralago?) is an effective and safe generic product. 展开更多
关键词 Parkinson’s Disease RASAGILINE generic Antiparkinsonian drugs HEALTH-RELATED Quality of Life
下载PDF
他汀类药物仿制药与原研药的疗效和安全性比较的系统评价
13
作者 邢晓璇 王可 +4 位作者 张晓彤 王之舟 冯英楠 张兰 董宪喆 《中国医院用药评价与分析》 2024年第5期588-593,共6页
目的:系统评价他汀类药物仿制药与原研药在真实世界中的疗效和安全性,为临床用药选择提供循证依据。方法:计算机检索the Cochrane Library、MEDLINE、Embase、中国知网、中国生物医学文献服务系统、维普数据库和万方数据库,并查阅所获... 目的:系统评价他汀类药物仿制药与原研药在真实世界中的疗效和安全性,为临床用药选择提供循证依据。方法:计算机检索the Cochrane Library、MEDLINE、Embase、中国知网、中国生物医学文献服务系统、维普数据库和万方数据库,并查阅所获文献所附参考文献,收集他汀类药物仿制药与原研药的观察性研究(暴露组患者使用他汀类药物仿制药或原研药换为仿制药;非暴露组患者使用他汀类药物原研药),检索时限均为数据库建库至2023年7月。对符合纳入标准的研究进行资料提取后,采用纽卡斯尔-渥太华量表进行质量评价;运用RevMan 5.4统计软件进行Meta分析,同时进行描述性分析。结果:共纳入14项研究,其中3项为历史对照研究,11项为队列研究。Meta分析结果显示,仿制药与原研药总体主要不良心血管事件(MACE)发生率的差异无统计学意义(HR=1.07,95%CI=0.98~1.18,P=0.14),但氟伐他汀亚组分析结果提示仿制药的总体MACE发生率显著高于原研药;仿制药的总体全因死亡率显著高于原研药,但随访期为12个月的亚组分析结果显示差异无统计学意义(P>0.05);两组患者脑卒中住院率、不良反应发生率的差异均无统计学意义(P>0.05)。“换药”研究设计的定性描述结果表明,2项回顾性队列研究中,原研药换为仿制药组患者的总胆固醇、三酰甘油、低密度脂蛋白胆固醇水平降低程度与未换药组的差异无统计学意义(P>0.05);3项历史对照研究中,将原研药转换为仿制药并不会降低患者的疗效,然而原研药升高高密度脂蛋白胆固醇的效果显著优于仿制药。结论:他汀类药物的仿制药与原研药在临床疗效和安全性方面未见明显差异。 展开更多
关键词 他汀类药物 仿制药 原研药 有效性 安全性 系统评价
下载PDF
胃肠间质瘤患者服用甲磺酸伊马替尼仿制药和原研药的血药浓度及安全性评估
14
作者 陈欣然 刘明峰 +3 位作者 郭腾 杜丽英 侯娟 霍丽曼 《癌变.畸变.突变》 CAS 2024年第4期256-260,共5页
目的:比较胃肠间质瘤患者服用甲磺酸伊马替尼仿制药与原研药的血药浓度和不良反应,为临床医生和患者选择药物提供参考。方法:收集河北医科大学第四医院2020年12月至2023年12月,在门诊使用甲磺酸伊马替尼药物的胃肠间质瘤患者,分为原研... 目的:比较胃肠间质瘤患者服用甲磺酸伊马替尼仿制药与原研药的血药浓度和不良反应,为临床医生和患者选择药物提供参考。方法:收集河北医科大学第四医院2020年12月至2023年12月,在门诊使用甲磺酸伊马替尼药物的胃肠间质瘤患者,分为原研药甲磺酸伊马替尼片组,仿制药甲磺酸伊马替尼片组,以及仿制药甲磺酸伊马替尼胶囊组。通过高效液相色谱质谱联用仪检测患者用药后的伊马替尼及其代谢产物N-去甲基伊马替尼的血液稳态谷浓度。收集患者用药后的所有不良反应,并根据常见不良反应评估标准5.0版(CTCAE 5.0)确定不良反应等级。分析3组患者血药浓度和服药后不良反应的差异。结果:原研药组和两个仿制药组伊马替尼稳态谷浓度,N-去甲基伊马替尼稳态谷浓度,以及伊马替尼和N-去甲基伊马替尼稳态谷浓度之和,差异均无统计学意义(P均>0.05)。原研药和两个仿制药组不良反应等级也无显著差异(P均>0.05)。结论:甲磺酸伊马替尼原研药和两个仿制药安全性无显著差异。 展开更多
关键词 伊马替尼 仿制药 原研药 血药浓度 不良反应 队列研究
下载PDF
左乙拉西坦品牌药转为非专利药后对癫痫患儿的临床疗效和不良反应分析
15
作者 孙娜 石永晶 +3 位作者 余静洁 杨琳 黄绍平 李丹 《中国妇幼健康研究》 2024年第8期84-89,共6页
目的前瞻性观察左乙拉西坦(LEV)由品牌药转换为非专利药后对癫痫患儿的临床疗效和不良反应变化。方法以2019年4月至2020年12月在西安交通大学第二附属医院儿科就诊的196例癫痫患儿为研究对象,收集其从LEV品牌药转换为非专利药治疗前后... 目的前瞻性观察左乙拉西坦(LEV)由品牌药转换为非专利药后对癫痫患儿的临床疗效和不良反应变化。方法以2019年4月至2020年12月在西安交通大学第二附属医院儿科就诊的196例癫痫患儿为研究对象,收集其从LEV品牌药转换为非专利药治疗前后的临床资料,并根据转换后疾病发作情况分为发作增加组、发作减少组及发作无变化组。分析转换前后各组LEV血药浓度、癫痫发作情况、不良反应及转换后发作增加患儿的临床特征。结果转换前LEV血药浓度为(8.09±2.42)μg/mL,转换后血药浓度为(8.28±2.17)μg/mL,经比较差异无统计学意义(t=0.521,P=0.831)。转换前LEV治疗剂量/血药浓度比值为(3.44±1.10)L/kg,转换后治疗剂量/血药浓度比值为(3.77±1.59)L/kg,经比较差异无统计学意义(t=0.723,P=0.762)。转换前LEV的治疗有效率为81.05%(154/190),转换为非专利药后有效率为75.79%(144/190),经比较差异无统计学意义(χ^(2)=1.555,P=0.212)。发病年龄小及联合治疗的患儿在转换后可能会出现发作增加,LEV品牌药转换为非专利药后,未见出现新的不良反应。结论LEV品牌药转为非专利药后对癫痫患儿治疗安全有效,对发病年龄小及联合治疗的患儿需要重点关注。 展开更多
关键词 左乙拉西坦 非专利药 转换 抗惊厥药物 血药浓度 有效率
下载PDF
国家集采左氧氟沙星氯化钠注射液仿制药疗效和安全性评价
16
作者 蔡鸿福 陈如月 +5 位作者 林靖雯 曾晓芳 王之舟 董宪喆 张兰 刘茂柏 《中国医疗保险》 2024年第7期5-10,共6页
目的:比较国家集中带量采购左氧氟沙星氯化钠注射液和原研药品治疗社区获得性肺炎的临床疗效与安全性。方法:回顾性收集福建省某大型三甲医院2020年10月20日至2022年10月20日诊断为CAP并使用左氧氟沙星氯化钠注射液的患者相关临床信息,... 目的:比较国家集中带量采购左氧氟沙星氯化钠注射液和原研药品治疗社区获得性肺炎的临床疗效与安全性。方法:回顾性收集福建省某大型三甲医院2020年10月20日至2022年10月20日诊断为CAP并使用左氧氟沙星氯化钠注射液的患者相关临床信息,采用倾向性评分匹配法调整组间差异,比较两组的有效性和安全性。结果:倾向评分匹配后,集采组纳入患者117例,原研组纳入患者117例。两组用药第七天临床治疗有效率、白细胞、中性粒细胞百分数、C反应蛋白、降钙素原、体温、给药疗程(天)比较,无统计学差异。两组用药后肝肾功能异常比较,无统计学差异。结论:国家集中带量采购左氧氟沙星氯化钠注射液与原研药品治疗CAP的效果与安全性相当。 展开更多
关键词 国家集中带量采购 左氧氟沙星氯化钠注射液 仿制药 原研药 疗效
下载PDF
仿制与原研利伐沙班预防髋膝关节置换术后深静脉血栓有效性与安全性比较
17
作者 蒲强红 蒋兴 +3 位作者 李燕 刘凯 闫冰 王永才 《中国药业》 CAS 2024年第18期98-100,共3页
目的 评估仿制与原研利伐沙班预防人工髋关节置换术(THA)或人工膝关节置换术(TKA)后深静脉血栓(DVT)的有效性与安全性。方法 收集医院关节外科2016年7月至2022年12月收治拟行THA(96例)或TKA(63例)的患者,按所用利伐沙班来源的不同分为... 目的 评估仿制与原研利伐沙班预防人工髋关节置换术(THA)或人工膝关节置换术(TKA)后深静脉血栓(DVT)的有效性与安全性。方法 收集医院关节外科2016年7月至2022年12月收治拟行THA(96例)或TKA(63例)的患者,按所用利伐沙班来源的不同分为原研组(91例)和仿制组(68例),并随访术后3个月内DVT与药品不良反应发生率。结果 原研组及仿制组术后DVT发生率分别为4.40%和5.88%,出血事件发生率分别为1.10%和0,其他不良反应(便秘、疼痛、下肢肿胀)发生率分别为3.30%和7.35%,组间比较均无统计学差异(P> 0.05)。结论 THA或TKA术后使用仿制与原研利伐沙班的有效性与安全性相当。 展开更多
关键词 利伐沙班 深静脉血栓 人工髋关节置换术 人工膝关节置换术 原研药 仿制药 有效性 安全性
下载PDF
阿托伐他汀仿制药治疗高脂血症疗效与安全性的多中心回顾性队列研究
18
作者 邢晓璇 刘雪莹 +4 位作者 王之舟 张晓彤 王可 董宪喆 张兰 《中国医疗保险》 2024年第9期44-52,共9页
目的:比较阿托伐他汀仿制药与原研药的临床疗效和安全性差异,为国家组织药品集采中选仿制药的临床合理使用、集采政策的落地执行提供真实世界的证据。方法:本研究为多中心、回顾性、队列研究,数据来源于国内10家医疗机构的门诊电子信息... 目的:比较阿托伐他汀仿制药与原研药的临床疗效和安全性差异,为国家组织药品集采中选仿制药的临床合理使用、集采政策的落地执行提供真实世界的证据。方法:本研究为多中心、回顾性、队列研究,数据来源于国内10家医疗机构的门诊电子信息系统。纳入2020年4月1日至2023年3月31日门诊首次处方阿托伐他汀仿制药(美达信)或原研药(立普妥)的患者,采用倾向性评分匹配法均衡两组患者基线特征,对两组患者用药后的血脂相关指标的改善情况、药物性肝损伤和肌肉症状发生率进行比较。结果:与原研药组相比,入组后6个月内仿制药组的LDL-C、非HDL-C、TC和TG水平较基线水平的降低值和降低百分比均无统计学差异,仿制药组出现药物性肝损伤诊断的患者比例少于原研药组,出现新增肌肉症状相关诊断患者比例无统计学差异。结论:在本研究中,阿托伐他汀仿制药与原研药在临床降脂效果和安全性方面基本相当。用阿托伐他汀仿制药替代原研药在真实诊疗环境中具有可行性。 展开更多
关键词 阿托伐他汀 仿制药 真实世界研究 疗效 安全性
下载PDF
利用计算模拟技术建立头孢呋辛酯片体内、外相关性溶出度评价方法
19
作者 彭洁 洪建文 +6 位作者 肖慧 郭英豪 李佩 罗嘉琳 李何杏 丁子珊 陈涛 《中国抗生素杂志》 CAS CSCD 北大核心 2024年第3期325-332,共8页
目的利用计算模拟技术,探索建立前体药物头孢呋辛酯片的体内外相关性预测模型,用于仿制药生物等效性评估。方法参考文献中头孢呋辛酯片口服给药后的PK数据,结合参比制剂的血药浓度数据,利用GastroPlus TM软件搭建头孢呋辛酯片药代动力... 目的利用计算模拟技术,探索建立前体药物头孢呋辛酯片的体内外相关性预测模型,用于仿制药生物等效性评估。方法参考文献中头孢呋辛酯片口服给药后的PK数据,结合参比制剂的血药浓度数据,利用GastroPlus TM软件搭建头孢呋辛酯片药代动力学模型;结合原研制剂在不同溶出条件、4种溶出介质(pH1.2盐酸溶液、pH4.0醋酸盐缓冲溶液、pH6.8磷酸盐缓冲溶液和水)中的体外溶出行为,筛选适宜的溶出条件;将在不同溶出介质中得到的溶出曲线作为体内释放曲线,预测头孢呋辛酯片在体内PK参数并与参比制剂的临床实测数据进行比较,探讨头孢呋辛酯片体内外相关的溶出度方法。结果成功建立了头孢呋辛酯片体内外相关的溶出度方法:桨法,转速为55 r/min,以pH4.0醋酸盐缓冲液900 mL为溶出介质。结论所建立的头孢呋辛酯片药代动力学预测模型,可用于仿制药的生物等效性虚拟评估,为该药物的质量与疗效一致性评价提供了新思路。 展开更多
关键词 计算模拟技术 头孢呋辛酯片 溶出曲线 体内外相关性模型 仿制药
下载PDF
基于WHO/HAI标准调查法的湖北省SGLT-2抑制剂类药物可及性研究
20
作者 曾露 王璐 +2 位作者 刘东 贡雪芃 魏安华 《药品评价》 CAS 2024年第3期265-269,共5页
目的了解湖北省钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂的可及性现状,为药品临床使用和政策制定提供参考依据。方法依据世界卫生组织/健康行动国际组织(WHO/HAI)的标准调查法,调查湖北省医疗机构SGLT-2抑制剂的可及性,采取关键人物访谈... 目的了解湖北省钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂的可及性现状,为药品临床使用和政策制定提供参考依据。方法依据世界卫生组织/健康行动国际组织(WHO/HAI)的标准调查法,调查湖北省医疗机构SGLT-2抑制剂的可及性,采取关键人物访谈法分析影响SGLT-2抑制剂可获得性及可负担性的关键因素。结果2018—2023年期间湖北省医疗机构SGLT-2抑制剂的配备数量和可获得性呈递增趋势,三级医院普遍高于二级医院。其中达格列净可获得性最好,由2018年可获得性差(<25%)增加为2023年的可获得性好(>75%),其次为恩格列净,其他药物可获得性相对较差。影响可获得性因素主要为药品价格、药品是否纳入医保和药品是否集采等。从药品可负担性出发,此类药物总体较差(药物30 d治疗费用均大于最低日薪1倍),卡格列净、艾托格列净和恩格列净部分仿制药国内价格低于国际参考价,影响可负担性因素主要为医保覆盖情况及报销比例、药品价格和患者及家庭收入等。结论SGLT-2抑制剂在湖北省内的药品价格、可获得性及可负担性均有待进一步改善。随着这类药物治疗地位提升及临床需求增加,期望相关部门可从集采、医保、基本药物及药品研发生产等政策方面促进调整。 展开更多
关键词 SGLT-2抑制剂 可获得性 可负担性 原研药 仿制药
下载PDF
上一页 1 2 61 下一页 到第
使用帮助 返回顶部